Scholarlink

Objectives <p>This study evaluated the diagnostic and prognostic value of serum bone metabolism markers—osteocalcin and β-Cross-Laps—in patients with type 2 diabetes mellitus (T2DM) undergoing intraosseous dental implantation.</p> Methods <p>A blind randomized prospective clinical study was conducted between 2023 and 2025 involving 73 patients with partial or complete edentulism. Patients were randomly assigned to two groups: (1) Group A: 37 patients received UV-photofunctionalized implants (154 implants). (2) Group B: 36 patients received non-UV-photofunctionalized implants (148 implants). Serum osteocalcin and β-Cross-Laps were measured preoperatively, 1&#xa0;month postoperatively, and 3&#xa0;months after implantation using enzyme-linked immunosorbent assay (ELISA). Clinical and radiological outcomes included implant survival, marginal bone loss (MBL), probing pocket depth (PPD), bleeding on probing (BOP), resonance frequency analysis (RFA), and prosthetic success.</p> Results <p>Significant correlations were observed between serum osteocalcin and β-Cross-Laps concentrations and implant success rates. Implant failure occurred more frequently in patients with low osteocalcin and elevated β-Cross-Laps. Implant survival over 3&#xa0;years was 95.2% in Group A and 92.8% in Group B.</p> Conclusion <p>Monitoring serum osteocalcin and β-Cross-Laps provides valuable associative information regarding bone metabolism and implant outcomes in T2DM patients. Further studies are warranted to establish predictive modeling and individualized treatment strategies, need for validation through larger multicenter studies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Bone Metabolism Markers in Type 2 Diabetes Mellitus Patients with Dental Implants

  • 期刊论文

  • 发表日期：

    2026年5月7日

查看全文
  • Hakob Khachatryan,
  • Gagik Hakobyan

摘要

Objectives

This study evaluated the diagnostic and prognostic value of serum bone metabolism markers—osteocalcin and β-Cross-Laps—in patients with type 2 diabetes mellitus (T2DM) undergoing intraosseous dental implantation.

Methods

A blind randomized prospective clinical study was conducted between 2023 and 2025 involving 73 patients with partial or complete edentulism. Patients were randomly assigned to two groups: (1) Group A: 37 patients received UV-photofunctionalized implants (154 implants). (2) Group B: 36 patients received non-UV-photofunctionalized implants (148 implants). Serum osteocalcin and β-Cross-Laps were measured preoperatively, 1 month postoperatively, and 3 months after implantation using enzyme-linked immunosorbent assay (ELISA). Clinical and radiological outcomes included implant survival, marginal bone loss (MBL), probing pocket depth (PPD), bleeding on probing (BOP), resonance frequency analysis (RFA), and prosthetic success.

Results

Significant correlations were observed between serum osteocalcin and β-Cross-Laps concentrations and implant success rates. Implant failure occurred more frequently in patients with low osteocalcin and elevated β-Cross-Laps. Implant survival over 3 years was 95.2% in Group A and 92.8% in Group B.

Conclusion

Monitoring serum osteocalcin and β-Cross-Laps provides valuable associative information regarding bone metabolism and implant outcomes in T2DM patients. Further studies are warranted to establish predictive modeling and individualized treatment strategies, need for validation through larger multicenter studies.